Alerta

C/EBPβ和/或CXCL10作为靶点在脓毒症相关脑病的诊断与治疗中的应用

Absstract of: CN122440826A

本发明公开了一种C/EBPβ和/或CXCL10作为靶点在脓毒症相关脑病的诊断与治疗中的应用，涉及生物医学领域。本发明首次揭示了一条在脓毒症相关脑病中驱动神经炎症与认知损伤的新信号通路：转录因子C/EBPβ通过直接结合并激活CXCL10的转录，进而诱导小胶质细胞发生NLRP3炎性小体介导的焦亡。焦亡的小胶质细胞释放大量炎症因子，导致神经元突触损伤与凋亡，最终引发认知功能障碍。基于此，本发明提出了将C/EBPβ和CXCL10作为治疗SAE的药物靶点（如开发其抑制剂或中和抗体）以及作为辅助诊断SAE的生物标志物的全新用途，为SAE的防治提供了新的策略和工具。

一种检测神经丝轻链蛋白的抗体及其应用

Absstract of: CN122444867A

本发明公开了检测神经丝轻链蛋白的抗体及其应用，具体涉及检测神经丝轻链蛋白的抗体和试剂盒，基于该抗体及试剂盒能够准确的检测神经丝轻链蛋白的存在。

COMPOSITION FOR DETECTING AND DELIVERING COPPER IONS COMPRISING CARBON NANOPARTICLES

Absstract of: KR20260115290A

0001a 본 발명은 구리 이온 탐지 및 전달을 위한 탄소 나노입자에 관한 것으로 구체적으로는 황이 탄소와 섞여 있어 구리 이온을 탐지할 수 있고, 구리 이온을 내부에 포집하고 있어 생체 내로 구리 이온을 전달할 수 있는 나노입자에 관한 것이다.

BRAWNIN AGONISTS FOR USE IN THE TREATMENT OF AXONAL METABOLIC DISORDERS

Absstract of: US20260210943A1

Using primary mouse neuronal cultures and mouse models, the present inventors have highlighted the role of a new effector, BRAWNIN, in neuronal metabolic balance and cortical axon branching. The present inventors have shown that BRAWNIN expression is necessary and sufficient for cortical axon branching. The present inventors have particularly demonstrated that BRAWNIN expression allows completely restoring impaired axon branching phenotypes in an impaired axon development mouse model. The present invention therefore pertains to a BRAWNIN agonist for use in the treatment of axonal metabolic disorders. The present invention further pertains to screening methods for the identification of novel therapeutic compounds based on BRAWNIN expression in a cellular model.

BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR

Absstract of: US20260209329A1

Aspects of the disclosure relate to polypeptides comprising a signal peptide, an antigen-binding domain that specifically binds TGF-β, a peptide spacer, a transmembrane domain, and an endodomain. When expressed in a cell, the polypeptides are capable of not only neutralizing the TGF-β but also specifically triggering T-cell activation in the presence of TGF-β. T-cell activation spurs the immune cell to produce immunostimulatory cytokines and proliferate, thus turning TGF-β from an immunosuppressive signal to an activating stimulus.

PEPTIDE BIOMARKER

Absstract of: US20260210980A1

The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.

Organic Electrolyte-Gated Field Effect Transistor Biosensor

Absstract of: US20260210903A1

0000 An organic electrolyte-gated field effect transistor biosensor contains a microfluidic channel structure formed from a dielectric thermoplastic material. A biorecognition entity immobilized within the microfluidic channel allows the biosensor to detect the presence or concentration of an analyte in an electrolyte fluid placed within the channel. The dielectric material separates the microfluidic channel from the gate electrode and from the semiconductor material connecting the drain and source electrodes, and protects the gate electrode and the semiconductor material from direct contact with the electrolyte fluid in the microfluidic channel, to provide the biosensor with a high capacitance. Methods of fabricating the biosensor by monolithic 3D printing are also provided.

METHODS FOR PREDICTIVE MODELING OF ALZHEIMER'S DISEASE AND PROGRESSION

Absstract of: WO2026156364A1

Provided herein is the identification of target proteins for determination of clinical aspects of Alzheimer's disease in a subject. Further provided are methods for diagnosing Alzheimer's disease, determining the progression or rate of memory decline of Alzheimer's disease, and predicting amyloid-tau status, brain amyloidosis status, and plasma p-tau217 status of a subject, using predictor value comparison to thresholds. Also provided are methods of selecting a subject for inclusion in a clinical trial, methods for treating the subject in need thereof, and kits providing the same.

APPARATUS AND METHOD FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT SUBTYPE

Absstract of: WO2026155314A1

A dementia subtype diagnosis apparatus according to an embodiment of the present invention comprises: a data acquisition unit for collecting first protein data for effective protein candidates from a blood sample; a data processing unit for generating second protein data from the first protein data on the basis of an artificial intelligence analysis module, and generating combined protein data by combining the first protein data and the second protein data; and a diagnosis unit for determining a dementia subtype by using the combined protein data.

Biomarker Detection Using Layered Receptor and Electrode Configuration

Absstract of: US20260210956A1

0000 Herein disclosed is configuring a layered receptor with at least one layer comprising graphene oxide and an biomarker binding layer configured to bind with a targeted biomarker, connecting a working electrode comprising carbon nanotubes (CNT) and a reference electrode to the layered receptor, and detecting events comprising the targeted biomarker binding layer with the biomarker binding layer, by measuring changes in impedance to a plurality of frequencies of an alternating current voltage signal applied through a patient's body fluid between the working electrode and the reference electrode. The layered receptor may further comprise a plurality of self-assembled layers, comprising, in sequence, a layer abutting the CNT and comprising a polymer and metal nanoparticles, a layer comprising an organosulfur, the graphene oxide layer and the biomarker binding layer. The biomarker binding layer may comprise Syn-211, LB509 or 5G4. The targeted biomarker may be alpha-synuclein. An implementation may report biomarker concentrations in real-time based on detected binding events.

USE OF GDF-15 AS A NOVEL BIOMARKER

Absstract of: WO2026154393A1

The present disclosure relates to use of GDF-15 as a novel biomarker for diagnosing, monitoring early-stage cancer, insulin resistance, and autoimmune diseases. Further, the present disclosure also relates to a multipurpose kit and personalized treatment across multiple health domains. Additionally, the present disclosure deals with an AI- driven personalized treatment and point of care (POC) platform using GDF-15 biomarker. There is a disclosure about dual biomarker system comprising GDF 15 and additional biomarker.

BIOMARKERS FOR MULTIPLE SCLEROSIS (MS) DIAGNOSIS AND TREATMENT

Absstract of: WO2026153996A1

The present disclosure provides methods of diagnosing and treating multiple sclerosis (MS) using an anti-CD3 antibody, and methods of monitoring progression of MS and/or treatment.

BUCCAL SWAB BIOMARKERS FOR SCHIZOPHRENIA

Absstract of: WO2026156063A1

Provided are methods for diagnosing and treating schizophrenia based on the presence of biomarkers for schizophrenia. The biomarkers can comprise specificity protein 4 (SP4) mRNA and heat shock protein 60 (HSP60) protein.

METHODS OF TREATING A COGNITIVE IMPAIRMENT

Absstract of: AU2025226972A1

The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.

METHODS FOR CLASSIFYING, DETECTING AND TREATING BIOLOGICAL DISEASES

Absstract of: AU2024399715A1

The current disclosure provides for methods and compositions for classifying subjects having different biological states. The disclosure describes a method comprising: filtering sequence data obtained from a sample from a subject based on long non-coding RNA (lncRNA) and/or pseudogene RNA (pgRNA), and/or the reference genome; determining a biological state classification of the subject by providing the filtered sequence data to one or more machine learning classifiers as input, wherein the one or more machine learning classifiers is trained to output biological state classifications based on filtered sequence data of a training data set.

B-ISOXAZOLE DERIVATIVES, DIAGNOSTIC COMPOSITIONS; AND METHODS RELATED THERETO

Absstract of: AU2024401251A1

The present application relates to novel b-isox analogs for use in detecting misfolded proteins associated with neurodegenerative diseases, such as ALS, PD, AD, FTLD, and LATE. The present inventors identified and modified a specific site on the b-isox molecule, which significantly enhances detection capabilities. This modification also allows for the selection of analogs that either exhibit low background interference or alter cellular targets, based on the alteration of a functional group at critical site.

FLUORESCENCE-BASED ASSAY FOR IDENTIFICATION OF PROTAC LIGANDS FOR HECT-TYPE E3 LIGASES

Absstract of: US20260210948A1

0000 A method of identifying a ligand, which is a ligand for a target protein of interest, and which interacts with a homologous to E6AP C-terminus (HECT)-type E3 ligase; a composition comprising (a) a fluorescently labeled peptide comprising a PPxY motif, an E1 ubiquitin (Ub)-activating enzyme, an E2 Ub-conjugating enzyme, a HECT-type E3 ligase, Ub, adenosine triphosphate (ATP), and a reaction buffer or (b) a fluorescently labeled peptide comprising a PPxY motif, a Ub-charged E2 Ub-conjugating enzyme, a HECT-type E3 ligase, ATP, and a reaction buffer; and a composition comprising a ligand identified in accordance with the above method or a pharmaceutically acceptable salt thereof.

Methods of drug dosing based on early pharmacokinetics

Absstract of: US20260212981A1

0000 Provided is a computer-implemented method for predicting a pharmacokinetic feature for a drug administered to a subject, such as maximum concentration or time to maximum concentration. The method includes: contacting a fluid of the subject with an electrochemical aptamer-based sensor capable of detecting the drug, receiving a series of output values of the electrochemical aptamer-based sensor over a period of time, and using the series of output values to predict the pharmacokinetic feature.

COMPOSITIONS AND METHODS FOR SCREENING 4R TAU TARGETING AGENTS

Absstract of: US20260209296A1

Tau reporter compositions, tau reporter cells, and tau reporter animals are provided that comprise a four-repeat (4R) tau isoform linked to a first reporter protein and a three-repeat (3R) tau isoform linked to a second reporter protein that is different from the first reporter protein. Methods are provided for making such tau reporter cells and tau reporter animals and for using such tau reporter cells and tau reporter animals for assessing the activity of tau-targeting reagents.

PATHOLOGIC TDP-43 AS A BIOMARKER FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHY

Absstract of: US20260210981A1

Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.

ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED ALPHA-SYNUCLEIN AGGREGATES

Absstract of: US20260209322A1

0000 The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

Collaborative artificial intelligence method and system

Absstract of: AU2026205405A1

A method for operating a virtual assistant, the method comprising: at an electronic device: initiating a virtual assistant operable to connect a user with one or more repositories of health information; identifying, by the virtual assistant, the user based on one or more user-specific features; associating a subset of the health information with the user based on the identification of the user, at least a portion of the subset of the health information relating to a particular subject; responsive to receiving a user input via the virtual assistant: accessing, by the virtual assistant, the one or more repositories of information; identifying one or more documents within the one or more repositories as being relevant to the user input; extracting partial response data from the one or more documents; processing, by the virtual assistant, the partial response data in view of the user input to generate a complete response to the user input; and providing the complete response for broadcasting via an output device associated with the electronic device, wherein the steps of identifying one or more documents within the one or more repositories as being relevant to the user input and extracting partial response data from the one or more documents include: identifying at least one parameter in the user input; identifying at least one intent associated with the user input, the at least one intent selected from a pool of intents identified from a plurality of intents based on the at leas

GENE THERAPIES FOR LYSOSOMAL DISORDERS

Absstract of: US20260209718A1

0000 The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD). The disclosure also provides expression constructs comprising a transgene encoding progranulin or a portion thereof. The disclosure provides methods of treating FTD by administering such expression constructs to a subject in need thereof.

COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY

Absstract of: US20260207789A1

0000 The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

METHOD TO DETECT AND TREAT PERIPHERAL NEUROPATHY

Nº publicación: US20260210976A1 23/07/2026

Applicant:

OHIO STATE INNOVATION FOUND [US]
Ohio State Innovation Foundation

Absstract of: US20260210976A1

Disclosed herein is a kit to detect and determine post-synaptic density protein-95 (PSD-95) levels in subjects with peripheral neuropathy. Also disclosed herein, is a method of treating or preventing neuropathy in a subject. The method comprises detecting PSD-95 levels in a sample from the subject, using the kit disclosed herein and when the PSD-95 level differs from a control, the subject is treated for neuropathy.